Jiuzhou Pharmaceutical(SH:603456) Sou Hu Cai Jing·2025-08-06 16:23Financial Performance - The company's operating revenue for the first half of 2025 was 2.87 billion yuan, representing a year-on-year increase of 3.9% [2] - The net profit attributable to shareholders was 525.83 million yuan, up 10.7% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 525.85 million yuan, reflecting a 12.4% increase compared to the previous year [2] - The basic earnings per share (EPS) was 0.59 yuan, an increase of 11.32% year-on-year [2] Profitability Metrics - The gross profit margin for the second quarter of 2025 was 37.45%, which is an increase of 0.03 percentage points from the previous quarter and up 2.24 percentage points from the same period last year [2] Cash Flow - The net operating cash flow for the first half of 2025 was 845 million yuan, showing a significant year-on-year growth of 164.5% [2] Historical Performance - The company's projected operating revenues for 2022, 2023, and 2024 are 5.445 billion yuan, 5.523 billion yuan, and 5.161 billion yuan, with year-on-year growth rates of 34.01%, 1.44%, and -6.57% respectively [5] - The net profit attributable to shareholders for the same years is projected to be 921 million yuan, 1.033 billion yuan, and 606 million yuan, with year-on-year growth rates of 45.28%, 12.17%, and -41.34% respectively [5] Company Overview - The company, established on July 13, 1998, specializes in providing one-stop pharmaceutical custom research and development (CDMO) services for global pharmaceutical companies, biotechnology firms, and research institutions [5] - The registered capital of the company is approximately 889.45 million yuan [5] Leadership - The chairman of the company, Hua Lirong, has a master's degree and is a senior economist [4] - In 2022, Hua Lirong was ranked 236th on the "New Fortune 500 Rich List" with a wealth of 20.02 billion yuan, making her the richest woman in Taizhou, Zhejiang [4]